Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $43.20

Palvella Therapeutics (NASDAQ:PVLA) has received an average recommendation of “Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $43.50.

Several research analysts have recently weighed in on PVLA shares. Stifel Nicolaus began coverage on shares of Palvella Therapeutics in a research note on Wednesday. They set a “buy” rating and a $45.00 price objective on the stock. TD Cowen started coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Jones Trading began coverage on Palvella Therapeutics in a report on Tuesday. They set a “buy” rating and a $45.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Trading Down 0.6 %

NASDAQ PVLA opened at $27.76 on Tuesday. The company has a market cap of $311.49 million, a PE ratio of -2.29 and a beta of 0.54. The business’s 50 day simple moving average is $19.95. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $29.27.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PVLA. Citadel Advisors LLC bought a new position in Palvella Therapeutics during the fourth quarter worth about $125,000. Toronto Dominion Bank acquired a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $159,000. Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics during the fourth quarter worth approximately $171,000. Cresset Asset Management LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at approximately $251,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Palvella Therapeutics in the fourth quarter valued at approximately $256,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.